Skip to Content
Søg Menu
Vi dækker

ASH | American Society of Hematology Meeting & Exposition

ASH 2023

Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymfom Play the Video

Abstracts fra ASH 2023

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ Hæmatologi / BestPractice Nordic

ASH 2023: FDA Approves Gene Therapies for Sickle Cell Disease

/ Hæmatologi / BestPractice Nordic

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ Hæmatologi / BestPractice Nordic

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

/ Hæmatologi / BestPractice Nordic

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ Hæmatologi / BestPractice Nordic

Don’t Miss Out on ASH 2023 

/ Hæmatologi / BestPractice Nordic

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Hæmatologi / Jad Othman

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

/ Hæmatologi / Jason Westin

Undiagnosed and Unrecognized Patients with a High Bleeding Score

/ Hæmatologi / Eva Birgitte Leinøe

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Hæmatologi / Pieter Sonneveld

No Increased Risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Hæmatologi / Jeff P. Sharman
Tarec Christoffer El-galaly

Opsigtvækkende fremskridt på EHA for behandling af lymfom

/ Tarec Christoffer El-Galaly
EHA24Lymfom Play the Video

Dansk-Norsk Aften ASH 2024

BestPractice Nordic er glade for at kunne invitere til Dansk-Norsk Aften ASH 2024 i San Diego. Dansk-Norsk Aften vil være en faglig og social begivenhed, hvor vi inviterer specialister, der deltager på ASH i San Diego til at mødes og diskutere og perspektivere highlights og netværke. Programmet starter med en videnskabelig opsummering af nyheder og highlights. Vi slutter af med en hyggelig middag.

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Hæmatologi / Paolo Ghia

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

/ Hæmatologi / Alessandra Tedeschi

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B-Cell Lymphoma

/ Hæmatologi / Gabriel Brisou

ERG Deficiency Syndrome – Maybe a New Disease

/ Hæmatologi / Hamish S. Scott / Christopher Hahn

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Hæmatologi / Jeff P. Sharman

Hæmatologi 2023

  • Meet the Experts
  • 2023
Get access

Mere fra ASH 2023

Amer Zeidan

New Data on Oral Decitabine in MDS: Real-Life Analysis and Outcomes from ASH2023

/ Amer Zeidan
ASH23 Play the Video
Martin Hutchings

Opdaterede data viser fortsat komplet respons hos over 50% af patienter behandlet med glofitamab for r/r storcellet B-celle lymfom

/ Martin Hutchings
ASH23B-celle lymfomLymfom Play the Video
Mats Jerkeman

Key Updates in Mantle Cell Lymphoma from ASH 2023

/ Mats Jerkeman
ASH23Lymfom Play the Video
Martin Hutchings

Opmuntrende resultater for patienter med aggressiv lymfom

/ Martin Hutchings
ASH23Lymfom Play the Video
Mats Jerkeman

CAR-T Cell Therapy as Second-Line Treatment for Elderly Patients with Relapsed/Refractory Large B-Cell Lymphoma

/ Mats Jerkeman
ASH23B-celle lymfom Play the Video
Agoston Gyula Szabo

Myelomatose: Interessante data fra investigator-initieret studier

/ Agoston Gyula Szabo
ASH23Myelomatose Play the Video
Peter Hillmen

New Standard of Care for Previously Untreated CLL

/ Peter Hillmen
ASH23CLL Play the Video

ASH2023 AI in Hematology: Enhancing Diagnostic Precision for Two Rare Blood Cancers

/ Andrew Srisuwananukorn
AIASH23 Play the Video
Jelena Jelicic

Advancing Prognostic Models in Diffuse Large B-Cell Lymphoma Treatment

/ Jelena Jelicic
ASH23B-celle lymfom Play the Video
Banu Aygun

REACH Study: Hydroxyurea’s 7-8 Year Impact on 600 African Children with Sickle Cell Anemia

/ Banu Aygun
ASH23BørnBehandling Play the Video
Paolo Ghia

CAPTIVATE Study: CLL Combination Therapy of Ibrutinib and Venetoclax

/ Paolo Ghia
ASH23CLL Play the Video
Fabian Mueller

CD19 CAR T-Cell Therapy: A New Frontier in Autoimmune Disease Remission

/ Fabian Mueller
ASH23CAR-T Play the Video
Hent flere

MEDtalks ASH 2022

CLL

The Latest Advancements in the Treatment of CLL

/ Hæmatologi / John Gribben

Ibrutinib + venetoclax: Ny behandlingsmulighed ved CLL behandling i første linje

/ Hæmatologi / Carsten Utoft Niemann

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

/ Hæmatologi / Carsten Utoft Niemann

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Hæmatologi / Arnon Kater

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

/ Hæmatologi / Barbara Eichhorst
Se oversigt

AML

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Hæmatologi / Nikolaj Juul Nitschke

In the Era of Personalized Treatment and Targeted Therapies

/ Hæmatologi / Sergio Giralt

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Hæmatologi / Mark Levis

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Hæmatologi / Christine Ryan

CLL – The impact of using ibrutinib as front-line treatment

/ Hæmatologi / Ryan Jacobs

Myelomatose

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Hæmatologi / Eunice Wang

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

/ Hæmatologi / Roch Houot

Superior efficacy of Iptacopan in PNH patients

/ Hæmatologi / Régis Peffault De Latour

CLL – Update fra ASH 2022

/ Hæmatologi / Carsten Utoft Niemann

New potential key pathway in patients with ALL

/ Hæmatologi / Signe Modvig

Mere fra ASH 2022

Jennifer R. Brown

Significant longer PFS among patients who received zanubrutinib vs ibrutinib

/ Jennifer R. Brown
ASH22CLL Play the Video
Matthew Davids

Several interesting combinations of therapies with Calquence for patients with CLL

/ Matthew S. Davids
ASH22CLL Play the Video
Jad Othman

UK NCRI AML19 Trial – Liposomal daunorubicin and cytarabine had a significant survival benefit

/ Jad Othman
ASH22AML Play the Video
Hent flere

MEDtalks fra ASH 2021

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

/ Hæmatologi / Paul G. Richardson

Maintenance therapy: Oral azacitidine in patients with AML improves long-term overall survival

/ Hæmatologi / Andrew Wei

CAR-T-terapi til behandling av storcellet B-cellelymfom

/ Hæmatologi / Alexander Fosså

Relapse vaccine is a promising treatment for patients with AML

/ Hæmatologi / Bjørn Tore Gjertsen

CAR T Cell Therapy – a new standard of care for 2L treatment of R/R in Large B-cell Lymphoma

/ Hæmatologi / Manali Kamdar

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Hæmatologi / Matthew S. Davids

How can we use Minimal Residual Disease in the treatment of CLL?

/ Hæmatologi / Paolo Ghia

Safe to use Belantamab Mafodotin for transplant-ineligible patients with newly diagnosed multiple myeloma

/ Hæmatologi / Evangelos Terpos

The use of FDG PET/CT positivity as an indication for consolidation in myeloma patients after ASCT

/ Hæmatologi / Fredrik Schjesvold

PFS of 63% after 5 years for patients with multiple myeloma in maintenance therapy with lenalidomide and dexamethasone

/ Hæmatologi / Laura Rosiñol

Nye behandlinger med antistoffer til patienter med myelomatose patienter

/ Hæmatologi / Torben Plesner

Real-world outcomes of axi-cel treatment of large B-cell lymphoma

/ Hæmatologi / Frederick L. Locke

ASH 2021: Flere opsigtsvækknede resultater for behandling af lymfomer

/ Hæmatologi / Judit Mészáros Jørgensen

The best treatment sequence for first-, second-, and third-line therapy for patients with relapsed multiple myeloma

/ Hæmatologi / Claudio Cerchione

MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients

/ Hæmatologi / Talha Munir

Abstracts fra ASH 2021

The ASH Annual Meeting provides several resources on COVID-19 in hematology

/ Hæmatologi / BestPractice Nordic

Long-term remission found with combination therapy for young patients with CLL

/ Hæmatologi / BestPractice Nordic

Isatuximab + RVd bedrer MRD negativitet og prognose ved myelomatose

/ Onkologi / BestPractice Nordic

New prophylactic therapy for patients with hemophilia A and B

/ Hæmatologi / BestPractice Nordic

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

/ Hæmatologi / BestPractice Nordic
Se oversigt

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Indhold fra ASH 2020

Post ASH: Lovende resultater for venetoclax ved behandling af AML

/ Michael Tøstesen
AMLASH20 Play the Video

ASH2020: Outcome efter CHOP-lignende behandling ved nodal perifer T-celle lymfom

/ Ahmed Ludvigsen Al-Mashhadi
LymfomT-cellerASH20 Play the Video

ASH2020: Ny fremtidig behandlingsmulighed for myelomatose

/ Agoston Gyula Szabo
MyelomatoseASH20 Play the Video
Hent flere

Back to top